With a new production line up and running at its latest facility in the greater Boston area, family-owned German CDMO Rentschler Biopharma is eager to court new clients.
Rentschler this week revealed that the production line at its site in Milford, Massachusetts (formerly known as the Rentschler Biopharma Manufacturing Center), is now fully operational. The company already has one “major project” underway utilizing the new production tech, plus several additional projects in the pipeline, Rentschler said in a press release.
Rentschler started construction on the new Milford plant back in the summer of 2021. The sprawling site—which includes 22,000 square feet of clean room space and four new 2,000-liter bioreactors—is conveniently located next to a separate facility Rentschler acquired from Shire in 2019 when the CDMO made its first foray into the United States.
At the time of the groundbreaking in 2021, Rentschler said the highly-automated facility would feature cutting edge manufacturing tech like advanced analytics yield optimization, virtual-reality enabled operations and no-touch batch releases.
The activation of the production line marks the completion of the biggest investment in Rentschler’s more than 150-year history, the company said. Rentschler says it recently completed the first engineering run of a 2,000-liter batch and, with the line fully up and running, the company has doubled its global manufacturing capacity.
The new Milford site is designed to crank out a range of drugs, though it will mainly focus on production of highly complex molecules, Rentschler said.
With the completion of the latest expansion project, Rentschler’s Milford campus now sports a total of three production lines.
Meanwhile, amid the changing CDMO landscape, Rentschler will continue to be a stalwart production partner, Tom Roberts, president of Rentschler Biopharma and general manager in the U.S., said in a statement.
“In light of evolving industry legislation, we remain committed to supporting our clients responsibly and contributing positively to both national interests and global health advancements,” he said, likely referring to the BIOSECURE Act and its associated uncertainties.
Over the last five years, Rentschler has expanded the Milford site it bought from Shire from 93,000 square feet to 138,000 square feet.
Headquartered in Laupheim, Germany, Rentschler currently employs about 1,400 people, according to the company’s LinkedIn profile. Aside from its sites in Germany and the U.S., the company operates a third campus in Stevenage in the United Kingdom dedicated to advanced medicines such as cell and gene therapies.
Read Again https://news.google.com/rss/articles/CBMifGh0dHBzOi8vd3d3LmZpZXJjZXBoYXJtYS5jb20vcGhhcm1hL2NkbW8tcmVudHNjaGxlci1leWVzLW1vcmUtcHJvZHVjdGlvbi1wcm9qZWN0cy1pdC1yZXZzLW1hbnVmYWN0dXJpbmctbGluZS1uZXctbWEtZmFjaWxpdHnSAQA?oc=5Bagikan Berita Ini
0 Response to "CDMO Rentschler eyes more production projects as it revs up manufacturing line at new MA facility - FiercePharma"
Post a Comment